Medios AG (OTCMKTS:MEDOF – Get Free Report) was the target of a significant drop in short interest in September. As of September 15th, there was short interest totaling 66 shares, a drop of 88.2% from the August 31st total of 561 shares. Based on an average daily trading volume, of 0 shares, the days-to-cover ratio is presently ∞ days.
Medios Price Performance
MEDOF opened at C$13.64 on Friday. The company’s 50 day simple moving average is C$13.64 and its 200-day simple moving average is C$13.64. Medios has a one year low of C$13.64 and a one year high of C$13.64.
Analyst Ratings Changes
Separately, Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating on shares of Medios in a report on Thursday, August 13th. One research analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy”.
About Medios
Medios AG, together with its subsidiaries, supplies specialty pharmaceutical drugs primarily in Germany. It operates through Pharmaceutical Supply and Patient-Specific Therapies segments. The Pharmaceutical Supply segment offers products on oncology, neurology, autoimmunology, ophthalmology, infectiology, and hemophilia diseases. The Patient-Specific Therapies segment manufactures medications for patients on behalf of pharmacies. This segment includes cytostatic infusion preparations, antibody therapies, virostatic and antibiotic medications, parenteral nutrition solutions, and investigational medicinal products.
See Also
- Five stocks we like better than Medios
- 3 Space Stocks to Watch as SpaceX Reshapes the Launch Market
- Dave’s Success Has Investors Split
- Hims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks
- Paychex Plunges, Providing the Entry Investors Have Been Waiting For
Receive News & Ratings for Medios Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medios and related companies with MarketBeat.com's FREE daily email newsletter.